PD-1/PD-L1阻断剂的临床研究进展
首发时间:2018-05-15
摘要:程序性细胞死亡蛋白1(PD-1)是一种抑制性免疫受体,它通过与配体PD-L1和PD-L2结合,抑制T细胞的增殖和其介导的免疫应答。阻断PD-1/PD-L1信号通路能逆转这一过程,从而增强抗肿瘤免疫活性。现已经开发了通过增强T细胞功能来阻断PD-1 / PD-L1途径的单克隆抗体(mAb)用于癌症免疫治疗。临床研究表明,PD-1/ PD-L1阻断剂显示出非常高的响应率,特别是对于黑色素瘤,非小细胞肺癌,肾细胞癌和膀胱癌。PD-1/ PD-L1阻断剂联合疗法能改善自身的不足,正在广泛研究之中。
关键词: 程序性细胞死亡蛋白1 程序性死亡配体1 肿瘤 免疫治疗 临床应用
For information in English, please click here
The clinical research progress of PD-1/PD-L1 blockade agents
Abstract:Programmed cell death protein 1 (PD-1) is an inhibitory immune receptor, which inhibits T cell proliferation and its mediated immune response by binding to its ligands, PD-L1 and PD-L2. Blocking the PD-1/PD-L1 signaling pathway reverses this process and enhances antitumor immunity. Monoclonal antibodies (mAbs) that block the PD-1 / PD-L1 pathway by enhancing T cell function have been developed for cancer immunotherapy.Clinical trials with PD-1 blockers have shown impressive response rates in patients, especially for melanoma, non-small-cell lung cancer, renal cell carcinoma, and bladder cancer. PD-1/PD-L1 blockades combination therapies which are being extensively studied can improve its own deficiency.
Keywords: PD-1;PD-L1;Cancer Immunotherapy Clinical application
引用
No.****
动态公开评议
共计0人参与
勘误表
PD-1/PD-L1阻断剂的临床研究进展
评论
全部评论0/1000